Clinical Trials
5
Active:4
Completed:0
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Retinoblastoma Phase II Expanded Access Clinical Trial
Phase 2
Recruiting
- Conditions
- Retinoblastoma
- Interventions
- Drug: Chemoplaque also referred to as Episcleral Topotecan
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT06679634
- Locations
- 🇺🇸
NewYork Presbyterian Morgan Stanley Children's Hospital, New York, New York, United States
Topotecan Episcleral Plaque for Treatment of Retinoblastoma
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT04156347
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Phase 1
Active, not recruiting
- Conditions
- Macular EdemaCentral Serous Retinopathy With Pit of Optic DiscCommotio RetinaeEpiretinal MembraneVitritisRadiation RetinopathyBranch Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT04120311
- Locations
- 🇺🇸
Stanford Medicine Ophthalmology, Palo Alto, California, United States
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Phase 1
Active, not recruiting
- Conditions
- Macula EdemaEpiretinal MembraneCentral Serous Retinopathy With Pit of Optic DiscBranch Retinal Vein OcclusionCommotio RetinaeRadiation RetinopathyVitritis
- Interventions
- Drug: Episcleral Celecoxib
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 3
- Registration Number
- NCT04120636
- Locations
- 🇺🇸
Stanford Medicine Ophthalmology, Palo Alto, California, United States
A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema
Phase 1
Active, not recruiting
- Conditions
- Refractory Diabetic Macular Edema
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Targeted Therapy Technologies, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04005430
- Locations
- 🇺🇸
Stanford Medicine Ophthalmology, Palo Alto, California, United States
News
No news found